Experimental drug combo targets brain cancer resistance
NCT ID NCT03514069
First seen Feb 25, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This early-phase study tests whether adding the experimental drug ruxolitinib to standard brain cancer treatment (radiation and temozolomide) is safe and tolerable for people with newly diagnosed aggressive brain tumors called grade III gliomas or glioblastoma. Ruxolitinib aims to block cancer cell growth, while temozolomide damages tumor DNA. About 60 participants will receive the combination to find the best dose and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.